secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bionano Genomics, Inc. (BNGO)
CIK:        0001411690
Form:       8-K
Filed at:   2026-05-13T20:03:04+00:00
Accession:  0001411690-26-000027
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bionano Q1 revenue $6.7M (+4% YoY); gross margin 49%; positive coding updates
-----------------------------------------------------------------------------

- Total revenue $6.7M (+4% vs $6.5M Q1 2025); consumables revenue $3.9M (+20%).
- Gross margin improved to 49% from 46% YoY; sold 8,178 nanochannel flow cells (+17%).
- Operating expenses cut 2% to $11.1M; adjusted op. expense +7% to $9.1M.
- New CPT code 81354 for OGM in constitutional genetics effective Jan 1, 2026, priced above microarray codes.
- Final CLFS shows 47% payment increase for CPT 81195 (OGM in hematologic malignancy) to $1,853.22.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411690/000141169026000027/0001411690-26-000027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411690/000141169026000027/bngo-20260513.htm
  HTML page:      https://secwatch.observer/filing/0001411690-26-000027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer